<?xml version="1.0" encoding="UTF-8"?>
<p>
 <italic>Favipiravir</italic>, a selective inhibitor of viral RNA polymerase, was developed to treat novel influenza. Based on its broad spectrum antiviral efficacy against various RNA viruses, including Ebola, clinical trials are ongoing. A nonrandomized controlled trial from China reported shorter virus disappearance times.
 <xref rid="jog14384-bib-0042" ref-type="ref">
  <sup>42</sup>
 </xref> Many case reports are available on the website of the Japan Society for Infective Diseases.
 <xref rid="jog14384-bib-0043" ref-type="ref">
  <sup>43</sup>
 </xref> However, favipiravir is contraindicated in pregnant patients as well as men and women who wish to conceive due to its strong teratogenicity.
</p>
